Contents:

I. SCOPE AND METHODOLOGY II. REPORT SYNOPSIS 1. Introduction Angiogenesis Segmentation of Angiogenesis Exhibit 1: Segmentation of Global Angiogenesis Therapeutic Products Market by Angiogenesis Modulators (Inhibitors and Stimulators) and Therapeutic Areas (Cancer, Cardiovascular and Other) 2. Global Market Analysis Exhibit 2: Angiogenesis Therapeutic Products (2005-2012) – Global Market Analysis (Current & Future) in US$ Million (Graphical Representation Included) 3. Angiogenesis Modulators Analysis by Geographic Region Inhibitors Exhibit 3: Angiogenesis Inhibitors (2005-2012) – Global Market Analysis (Current & Future) by Geographic Region for United States, Europe, Asia-Pacific and Rest of World in US$ Million (Graphical Representation Included) Exhibit 4: Angiogenesis Inhibitors (2006, 2009 and 2012) – Percentage Breakdown of Global Market Value by Geographic Region for United States, Europe, Asia-Pacific and Rest of World (Graphical Representation Included) Exhibit 5: Angiogenesis Inhibitors (2005-2012) - Global Analysis (Current & Future) of Patients Treated by Geographic Region for United States, Europe, Asia-Pacific and Rest of World in Million (Graphical Representation Included) Exhibit 6: Angiogenesis Inhibitors (2006, 2009 and 2012) – Percentage Breakdown of Patients Treated Globally by Geographic Region for United States, Europe, Asia-Pacific and Rest of World (Graphical Representation Included) Stimulators Exhibit 7: Angiogenesis Stimulators (2005-2012) – Global Market Analysis (Current & Future) by Geographic Region for United States, Europe, Asia-Pacific and Rest of World in US$ Million (Graphical Representation Included) Exhibit 8: Angiogenesis Stimulators (2006, 2009 and 2012) – Percentage Breakdown of Global Market Value by Geographic Region for United States, Europe, Asia-Pacific and Rest of World Analysis of Angiogenesis Disease Area by Geographic Region Cancer Exhibit 9: Angiogenesis Therapeutic Products for Cancer (2005-2012) – Global Market Analysis (Current & Future) by Geographic Region for United States, Europe, Asia-Pacific and Rest of World in US$ Million Exhibit 10: Angiogenesis Therapeutic Products for Cancer (2006, 2009 and 2012) – Percentage Breakdown of Global Market Value by Geographic Region for United States, Europe, Asia-Pacific and Rest of World Cardiovascular Exhibit 11: Angiogenesis Therapeutic Products for Cardiovascular Diseases (2005-2012) – Global Market Analysis (Current & Future) by Geographic Region for United States, Europe, Asia-Pacific and Rest of World in US$ Million Exhibit 12: Angiogenesis Therapeutic Products for Cardiovascular Diseases (2006, 2009 and 2012) – Percentage Breakdown of Global Market Value by Geographic Region for United States, Europe, Asia-Pacific and Rest of World Other Exhibit 13: Angiogenesis Therapeutic Products for Other Angiogenesis Based Diseases (2005-2012) – Global Market Analysis (Current & Future) by Geographic Region for United States, Europe, Asia-Pacific and Rest of World in US$ Million (Graphical Representation Included) Exhibit 14: Angiogenesis Therapeutic Products for Other Angiogenesis Based Diseases (2006, 2009 and 2012) – Percentage Breakdown of Global Market Value by Geographic Region for United States, Europe, Asia-Pacific and Rest of World Exhibit 15: List of Major Global Companies 4. Regional Market Analysis The United States Exhibit 16: Angiogenesis Therapeutic Products (2005-2012) – United States Market Analysis (Current & Future) in US$ Million (Graphical Representation Included) Major Companies in the United States Abbott Laboratories Adnexus Therapeutics, Inc. Alcon, Inc. Amgen, Inc. Ångstrom Pharmaceuticals, Inc Callisto Pharmaceuticals, Inc. Cardium Therapeutics, Inc. Celgene Corporation Collagenex Pharmaceuticals, Inc Eisai, Inc. Entremed, Inc. Genaera Corporation Genentech, Inc. Genvec, Inc. Genzyme Corporation Human Genome Sciences, Inc. Imclone Systems, Inc. Intradigm Corporation Merck & Co., Inc. (USA) OSI Pharmaceuticals, Inc. Oxigene, Inc Pfizer, Inc. The US Market Analysis by Type of Angiogenesis Modulators Exhibit 17: Angiogenesis Therapeutic Products (2005-2012) – United States Market Analysis (Current & Future) by Angiogenesis Modulators for Inhibitors and Stimulators in US$ Million (Graphical Representation Included) Exhibit 18: Angiogenesis Therapeutic Products (2006, 2009 and 2012) – Percentage Breakdown of United States Market Value by Angiogenesis Modulators for Inhibitors and Stimulators (Graphical Representation Included) Europe Exhibit 19: Angiogenesis Therapeutic Products (2005-2012) – European Analysis (Current & Future) in US$ Million (Graphical Representation Included) Major Companies in Europe Antisoma plc (UK) Astrazeneca plc (UK) Bayer Healthcare AG (Germany) F.Hoffmann-La Roche Ltd. (Switzerland) Merck KGaA(Germany) Novartis AG (Switzerland) UCB SA (Belgium) Angiogenesis Modulators Analysis by Geographic Region Inhibitors Exhibit 20: Angiogenesis Inhibitors (2005-2012) – European Market Analysis (Current & Future) by Geographic Region for Germany, United Kingdom, France, Switzerland and Rest of Europe in US$ Million (Graphical Representation Included) Exhibit 21: Angiogenesis Inhibitors (2006, 2009 and 2012) – Percentage Breakdown of European Market Value by Geographic Region for Germany, United Kingdom, France, Switzerland and Rest of Europe (Graphical Representation Included) Stimulators Exhibit 22: Angiogenesis Stimulators (2005-2012) – European Market Analysis (Current & Future) by Geographic Region for Germany, United Kingdom, France, Switzerland and Rest of Europe in US$ Million (Graphical Representation Included) Exhibit 23: Angiogenesis Stimulators (2006, 2009 and 2012) – Percentage Breakdown of European Market Value by Geographic Region for Germany, United Kingdom, France, Switzerland and Rest of Europe Asia-Pacific Exhibit 24: Angiogenesis Therapeutic Products (2005-2012) – Asia-Pacific Market Analysis (Current & Future) in US$ Million (Graphical Representation Included) Major Companies in Asia-Pacific Bionomics Ltd. (Australia) Chugai Pharmaceutical Co., Ltd. (Japan) Progen Industries Ltd. (Australia) Angiogenesis Modulators Analysis by Geographic Region Inhibitors Exhibit 25: Angiogenesis Inhibitors (2005-2012) – Asia-Pacific Market Analysis (Current & Future) by Geographic Region for Japan and Rest of Asia-Pacific in US$ Million (Graphical Representation Included) Exhibit 26: Angiogenesis Inhibitors (2006, 2009 and 2012) – Percentage Breakdown of Asia-Pacific Market Value by Geographic Region for Japan and Rest of Asia-Pacific (Graphical Representation Included) Stimulators Exhibit 27: Angiogenesis Stimulators (2005-2012) – Asia-Pacific Market Analysis (Current & Future) by Geographic Region for Japan and Rest of Asia-Pacific in US$ Million (Graphical Representation Included) Exhibit 28: Angiogenesis Stimulators (2006, 2009 and 2012) – Percentage Breakdown of Asia-Pacific Market Value by Geographic Region for Japan and Rest of Asia-Pacific (Graphical Representation Included) Rest of World Exhibit 29: Angiogenesis Therapeutic Products (2005-2012) – Rest of World Market Analysis (Current & Future) in US$ Million (Graphical Representation Included) Angiogenesis Modulators Analysis by Geographic Region Inhibitors Exhibit 30: Angiogenesis Inhibitors (2005-2012) – Rest of World Market Analysis (Current & Future) by Geographic Region for Latin America and Other^ in US$ Million (Graphical Representation Included) Exhibit 31: Angiogenesis Inhibitors (2006, 2009 and 2012) – Percentage Breakdown of Rest of World Market Value by Geographic Region for Latin America and Other (Graphical Representation Included) Stimulators Exhibit 32: Angiogenesis Stimulators (2005-2012) – Rest of World Market Analysis (Current & Future) by Geographic Region for Latin America and Other^ in US$ Million (Graphical Representation Included) Exhibit 33: Angiogenesis Stimulators (2006, 2009 and 2012) – Percentage Breakdown of Rest of World Market Value by Geographic Region for Latin America and Other (Graphical Representation Included) III. PRODUCT RESEARCH 1. Introduction Angiogenesis – The Growth of New Blood Vessels Global Growth Trends – Angiogenesis Therapeutic Products Exhibit 34: Global Market for Angiogenesis Therapeutic Products: Geographic Regions (Asia-Pacific, United States and Europe) Ranked by Projected CAGR for 2005 through 2012 (Graphical Representation Included) The Process The Types Sprouting Angiogenesis Role of Angioprotien in Sprouting of Angiogenesis Intussusceptive Angiogenesis Role of Intussusceptive Angiogenesis in Embryonic Vascular Network Configuration Therapeutic Angiogenesis Role of Therapeutic Angiogenesis in Various Diseases Delivery of Drugs in Cancer Therapy through Angiogenesis Angiogenic Therapy for Heart? 2. Modulators of Angiogenesis Growth Trends – Global Angiogenesis Therapeutic Products by Modulators Exhibit 35: Global Market for Angiogenesis Therapeutic Products: Angiogenesis Modulators (Stimulators and Inhibitors) Ranked by Projected CAGR for 2005 through 2012 (Graphical Representation Included) 2.1 Angiogenesis Inhibitors Growth Trends – Global Market for Angiogenesis Inhibitors Exhibit 36: Global Market for Angiogenesis Inhibitors: Geographic Regions (Asia-Pacific, United States, Europe ) Ranked by Projected CAGR for 2005 through 2012 (Graphical Representation Included) Natural Angiogenesis Inhibitors Angiostatin – A Potent Angiogenesis Inhibitor of Tumor Growth Heparin Hexasaccharide Fragment Interleukin-12 Placental Ribonuclease Inhibitor Retinoids Thrombospondin-1 (TSP-1) Role of TSP-1 as Autocrine Negative Regulator for Human Dendritic Cell Activation Cartilage Derived Inhibitor Angioarrestin Endostatin Platelet Factor-4 Metalloproteinase Inhibitors Interferon Alpha/Beta/Gamma Other 2.2 Angiogenesis Stimulators Growth Trends – Global Market for Angiogenesis Stimulators Exhibit 37: Global Market for Angiogenesis Stimulators: Geographic Regions (Asia-Pacific, United States and Europe) Ranked by Projected CAGR for 2005 through 2012 (Graphical Representation Included) Natural Angiogenic Stimulators Vascular Endothelial Growth Factor VEGF Splice Variants and Their Functions Role of VEGF in Various Diseases Effect of VEGF & bFGF on In-vivo and In-vitro Conditions Fibroblast Growth Factors Basic FGF Expression of bFGF (FGF2) in Various Diseases Alzheimer's Precursor Neural Cells of Mice Acidic FGF Role of aFGF in ADPKD Expression of aFGF in Alzheimer's Granulocyte Colony-Stimulating Factor Impact of G-CSF on Neutrophils The Usage of G-CSF in Pharma Industry Angiogenin Angiopoietin-1 Platelet Derived Endothelial Cell Growth Factor Uterine Cervical Cancers and Role of PD-ECGF Leptin Leptin’s MoA Midkine Placental Growth Factor Stimulation of Inflammation and Swelling – A Role of Placental Growth Factor Hepatocyte Growth Factor (HGF)/Scatter Factor (SF) Transforming Growth Factor (TGF) TGFa TGFß The TGFß receptor Other 3. Angiogenesis in Diseases Growth Trends – Global Market for Angiogenesis Therapeutic Areas Exhibit 38: Global Market for Angiogenesis Therapeutic Products: Major Angiogenesis Therapeutic Areas (Cardiovascular Disorders, Other* and Cancer) Ranked by Projected CAGR for 2005 through 2012 (Graphical Representation Included) 3.1 Remedy of Diseases with Angiogenesis Inhibitors Angiogenesis Inhibitors-Patient Demographics Exhibit 39: Angiogenesis Inhibitors (2005-2011): Global Analysis (Current & Future) of Patients Treated in Million Cancer Therapy – Role of Angiogenesis Global Market for Major Cancer Types Exhibit 40: Major Cancer Types (2005 & 2006): Global Market for Major Cancer Types – Breast, Colorectal, Lung and Prostate in US$ Million (Graphical Representation Included) Growth Trends – Global Market for Angiogenesis Therapeutic Products for Cancer Exhibit 41: Global Market for Angiogenesis Therapeutic Products for Cancer: Geographic Regions (Asia-Pacific, United States and Europe) Ranked by Projected CAGR for 2005 through 2012 (Graphical Representation Included) Cancer Therapy Angiogenesis Vs Conventional Conventional Cancer Treatments Surgery Radiation Therapy for Healing Cancer Chemotherapy Treatment Hormone Stimulation Therapy Process of Immuno Therapy Experimenting Phase Targeted Therapy Angiostatic Therapy Angiostatic Agents Angiolytic Photodynamic Therapy Researches in Development of Cancer Therapy Angiobalans Global Cancer Demographics Exhibit 42: Cancer Incidents (2006, 2011 & 2020): Estimates and Projections for Global Cancer Incidents in Million/Year with Mortality Percentage (Graphical Representation Included) Alzheimer’s Dermatology Cosmetic Dermatology Angiogenesis in Dermatology Angiogenesis Inhibitor Angiogenesis Stimulating Drugs Psoriasis Role of Angiogenesis in Psoriasis Rosacea MoA of Photoaging in Rosacea Pathogenesis Ophthalmology Age Related Macular Degeneration Advanced stage of vision loss Causes Characteristics of the disorder Detection process of the Disorder Medication Precautionary measure Types of AMD Non-Neo-vascular (dry) AMD Neo-vascular (wet) AMD Other Turmoil Based on Angiogenesis Rubeosis Iridis Neovascularization Neovascularization in Association with Angiogenesis Rheumatology Rheumatoid Arthritis Angiogenesis in Rheumatoid Arthritis – Pathogenic and Therapeutic Implications Skin Related Ailments Deficient Angiogenesis in Skin Diseases Osteoarthritis (OA), Angiogenesis and Inflammation Other Inflammatory Diseases Growth of New Blood Vessels in Inflammation Cause of joint swelling due to inflammation Endometriosis Symptoms of the Disease 3.2 Remedy of Diseases with Angiogenesis Stimulators Wound Care – Role of Angiogenesis Soluble Factors Responsible for Wound Angiogenesis Diabetic Foot Ulcers Angiogenesis in Cardiovascular Disorders Growth Trends – Global Market for Angiogenesis Therapeutic Products for Cardiovascular Disorders Exhibit 43: Global Market for Angiogenesis Therapeutic Products for Cardiovascular Disorders: Geographic Regions (United States, Asia-Pacific and Europe) Ranked by Projected CAGR for 2005 through 2012 (Graphical Representation Included) Ischemia Role of ASK 1 in Angiogenesis during Ischemia Role of NGF in Neo-Vascularization during Ischemic Conditions Congestive Heart Failure Root of CHF Detection of CHF Treatment of CHF Role of Angiogenesis in CHF Coronary Artery Disease Angina Heart Attack Heart Failures Arrhythmias Symptoms Identified for CAD Role of Angiogenesis in CAD Treatment Peripheral Vascular Disease Angiogenic Therapy for the Treatment of PVD Peripheral Artery Disease Therapeutic Angiogenesis in PAD Myocardial Infarction Treatment of Myocardial Infarction Using Non-Invasive Imaging of Myocardial Angiogenesis IV. MARKET DYNAMICS 1. Market Overview Global Market Analysis Exhibit 44 Angiogenesis Therapeutic Products (2005-2012) – Global Market Analysis (Current & Future) by Geographic Region for United States, Europe, Asia-Pacific and Rest of World in US$ Million (Graphical Representation Included) Exhibit 45 Angiogenesis Therapeutic Products (2006, 2009 and 2012) – Percentage Breakdown of Global Market Value by Geographic Region for United States, Europe, Asia-Pacific and Rest of World (Graphical Representation Included) 2. Major Companies in Angiogenesis Industry Abbott Laboratories (USA) Adnexus Therapeutics, Inc. (USA) Aeterna Zentaris, Inc. (Canada) Alcon, Inc. (USA) Amgen, Inc. (USA) Angiotech Pharmaceuticals, Inc. (Canada) Ångstrom Pharmaceuticals, Inc. (USA) Antisoma plc (UK) Astrazeneca plc (UK) Bayer Healthcare AG (Germany) Callisto Pharmaceuticals, Inc. (USA) Cardium Therapeutics, Inc. (USA) Celgene Corporation (USA) Chugai Pharmaceutical Co., Ltd. (Japan) Collagenex Pharmaceuticals, Inc. (USA) Eisai, Inc. (USA) Entremed, Inc. (USA) F.Hoffmann-La Roche Ltd. (Switzerland) Genaera Corporation (USA) Genentech, Inc. (USA) Genvec, Inc. (USA) Genzyme Corporation (USA) Human Genome Sciences, Inc. (USA) Imclone Systems, Inc. (USA) Intradigm Corporation (USA) Merck & Co., Inc. (USA) Merck KGaA (Germany) Novartis AG (Switzerland) OSI Pharmaceuticals, Inc. (USA) Oxigene, Inc. (USA) Pfizer, Inc. (USA) Progen Industries Ltd. (Australia) TAP Pharmaceutical Products, Inc. (USA) UCB SA (Belgium) 3. Major Activities in Angiogenesis Industry Nexavar® First FDA-Approved Drug Therapy for Liver Cancer Bionomics’ Anti-Cancer Compound Gains IND Approval Bilateral Agreement for Product Distribution between Cell Culture Service and TCS Cellworks Limited Coley Agrees to Acquisition by Pfizer Chugai Achieves Japanese Regulatory Approval for Tarceva® for NSCLC Treatment Synta Pharmaceuticals and GSK to Jointly Develop STA-4783… Atrium Biotechnologies Inc. will Become Atrium Innovations, Inc. ARIAD Announces Collaboration with ICON Medical to Develop and Commercialize Novel Deforolimus-Eluting Stents Bristol-Myers Squibb Acquires Adnexus Therapeutics Celera Enters Oncology Research Collaboration with Merck to Develop PharmacogenomicTests Avastin® and Chemotherapy Combination as First-line Treatment for NSCLC Approved in Europe Genentech Acquires Tanox System Medicine, Now a Wholly Owned Subsidiary of Cell Therapeutics, Inc ARIAD and Merck & Co., Inc. Announce Global Collaboration to Jointly Develop and Commercialize AP23573 - ARIAD's Novel mTOR Inhibitor - for Cancer Valentis and Urigen Merge National Cancer Institute Selects SR 16388 of SRI International Abbott and Genentech Announce Global, Integrated Research, Development and Commercialization Collaboration in Oncology Strategic Alliance Between Merck and Archemix Progen Industries is Now Progen Pharmaceuticals… Chugai Pharmaceutical Obtains Approval for Avastin® in Japan… Eisai Corporation Concludes the Deal to Acquire Morphotek, Inc… Celera and LabCorp® Announce Licensing Agreement to Commercialize Breast Cancer Testing Assays Paradigm Therapeutics Acquired by Takeda Pharmaceutical… ARIAD Grants Second Commercial License to its Patented ARGENT(TM) Cell-Signaling Regulation Technology for Development of New Cancer Therapies University of Bristol Awards Drug Discovery Contract to Galapagos NV… ImClone Systems Decides to Focus on its Proprietary Product, IMC-1121B … AngioGenetics Discovers New Mechanism for Blood Vessel Growth Seattle Genetics in Exclusive Worldwide Licensing Agreement with Genentech for SGN-40 Celgene Acquires API Unit from Siegfried Ltd. Otsuka and Chugai in Co-Promotion Deal Merck Buys Entire Stake in Sirna Therapeutics Genetix Acquires Applied Imaging Corporation InterMune and Roche Close Collaboration Agreement EntreMed Presents 2ME2 for Rheumatoid Arthritis Genzyme Acquires AnorMed Biomira Acquires ProlX Pharmaceuticals Pfizer Acquires PowderMed CTT Cancer Targeting Technologies and Karyon Ltd., Merge LibraGen and Sanofi-Aventis in Partnership for Microbial Diversity Applications Schering and Sonus Sign Global Licensing Agreement for TOCOSOL(R) Paclitaxel Merck Acquires Serono Sangamo Acquires Edwards' Angiogenesis Program AstraZeneca Acquires Cambridge Antibody Technology GSK and Shionogi Complete Initial Clinical Study for HIV Integrase Inhibitor Cardium Acquires Wound Healing Technology and Related Assets of TRC GSK and Galapagos Enter Into an Alliance for Osteoarthritis Drug Development Caliper Acquires Xenogen Pharmacopeia and Allergan Inc., in AMD Research Agreement Angiotech Pharmaceuticals Acquires Quill Medical Inc. Mayne Acquires SuperGen's North American Rights for Oncology Products Erbitux ® Approved in the US Corgentech Adopts New Name Angiotech and Genzyme Enter Into Strategic Collaboration for Developing Oncology Treatments Alcon and Amgen for Joint Development of Ophthalmology Therapies CancerVax Merges with Micromet Microbix and Angiogen Enter Into Marketing Agreement SuperGen Acquires Montigen Novartis Takes Over Chiron Amgen Completes Acquisition of Abgenix AEterna Zentaris’ Development of Cetrorelix to Continue In Japan Corautus Genetics Puts Forth VEGF-2 Studies Angiotech Pharmaceuticals Takes Over American Medical Instruments Amgen and Biovitrum in License Agreement Cryptome Takes Over HealthLinx AngioGenex Merges with eClic Merck Acquires Full US Rights to BLP25 Liposome Vaccine from Biomira Human Genome Science and Amgen in Licensing Agreement Protein Design Labs Changes Corporate Identity Bausch & Lomb and PTC Therapeutics in Research Collaboration Deal Sanofi-Aventis and Regeneron Pharmaceuticals Amend VEGF Collaboration OSI Pharmaceuticals Acquires Eyetech Pharmaceuticals Hybridon Adopts New Name Xencor and Centocor Enter into Monoclonal Antibodies Agreement Corautus in Diabetic Neuropathy Licensing Agreement Xantos and Cryptome Sign Agreement to Validate Cancer Leads Xantos and Atugen Sign Collaboration Agreement Allergan and Sanwa Kagaku Kenkyusho Develop Posurdex in Japan Corautus and Boehringer Ingelheim Sign Agreement to Produce VEGF-2 Bayer and Onyx Announce Access to Sorafenib (BAY 43-9006) 7TM Signs Therapeutic Angiogenesis Research Agreement with P&G Genzyme Acquires Verigen Antisoma and Raylo Sign Agreement for Manufacturing AS1411 Alcon and Morphochem Enter Into Alliance for Ophthalmic Compounds ImClone Systems Signs License Agreements Pfizer Takes Over Angiosyn 4. Regional Market Analysis A. The United States Market Analysis Cancer Incidents in the United States Exhibit 46: Cancer Incidents and Percentage of Deaths in the United States in 2005 and 2006 Exhibit 47: US Cancer Incidents (2006): No. of Cases by Type of Cancer – Prostate, Breast, Lung, Colorectal and Other (Graphical Representation Included) US Market for Interventional Peripheral Vascular Products Exhibit 48: Interventional Peripheral Vascular Products (2004 & 2009) – The US Market Analysis in US$ Million Analysis by Type of Angiogenesis Modulators Exhibit 49: Angiogenesis Therapeutic Products (2005-2012) – United States Market Analysis (Current & Future) by Angiogenesis Modulators for Inhibitors and Stimulators in US$ Million (Graphical Representation Included) Exhibit 50: Angiogenesis Therapeutic Products (2006, 2009 and 2012) – Percentage Breakdown of United States Market Value by Angiogenesis Modulators for Inhibitors and Stimulators (Graphical Representation Included) Analysis by Disease Area Exhibit 51: Angiogenesis Therapeutic Products (2005-2012) – United States Market Analysis (Current & Future) by Disease Area for Cancer, Cardiovascular and Other in US$ Million (Graphical Representation Included) Exhibit 52: Angiogenesis Therapeutic Products (2006, 2009 and 2012) – Percentage Breakdown of United States Market Value by Disease Area for Cancer, Cardiovascular and Other Exhibit 53: List of Major Companies in the United States B. Europe Market Analysis Exhibit 54: Angiogenesis Therapeutic Products (2005-2012) – European Market Analysis (Current & Future) in US$ Million (Graphical Representation Included) Analysis by Geographic Region Exhibit 55: Angiogenesis Therapeutic Products (2005-2012) – European Market Analysis (Current & Future) by Geographic Region for Germany, United Kingdom, France, Switzerland, and Rest of Europe in US$ Million (Graphical Representation Included) Exhibit 56: Angiogenesis Therapeutic Products (2006, 2009 and 2012) – Percentage Breakdown of European Market Value by Geographic Region for Germany, United Kingdom, France Switzerland, and Rest of Europe Analysis by Type of Angiogenesis Modulators Exhibit 57: Angiogenesis Therapeutic Products (2005-2012) – European Market Analysis (Current & Future) by Angiogenesis Modulators for Inhibitors and Stimulators in US$ Million (Graphical Representation Included) Exhibit 58: Angiogenesis Therapeutic Products (2006, 2009 and 2012) – Percentage Breakdown of European Market Value by Angiogenesis Modulators for Inhibitors and Stimulators (Graphical Representation Included) Analysis by Disease Area Exhibit 59: Angiogenesis Therapeutic Products (2005-2012) – European Market Analysis (Current & Future) by Disease Area for Cancer, Cardiovascular and Other in US$ Million (Graphical Representation Included) Exhibit 60: Angiogenesis Therapeutic Products (2006, 2009 and 2012) – Percentage Breakdown of European Market Value by Disease Area for Cancer, Cardiovascular and Other Exhibit 61 List of Major Companies in Europe European Angiogenesis Modulators Market by Country B1. Germany German Market Analysis Analysis by Type of Angiogenesis Modulators Exhibit 62: Angiogenesis Therapeutic Products (2005-2012) – German Market Analysis (Current & Future) by Angiogenesis Modulators for Inhibitors and Stimulators in US$ Million (Graphical Representation Included) Exhibit 63: Angiogenesis Therapeutic Products (2006, 2009 and 2012) – Percentage Breakdown of German Market Value by Angiogenesis Modulators for Inhibitors and Stimulators (Graphical Representation Included) B2. The United Kingdom UK Market Analysis Analysis by Type of Angiogenesis Modulators Exhibit 64: Angiogenesis Therapeutic Products (2005-2012) – United Kingdom Market Analysis (Current & Future) by Angiogenesis Modulators for Inhibitors and Stimulators in US$ Million (Graphical Representation Included) Exhibit 65: Angiogenesis Therapeutic Products (2006, 2009 and 2012) – Percentage Breakdown of United Kingdom Market Value by Angiogenesis Modulators for Inhibitors and Stimulators (Graphical Representation Included) B3. France French Market Analysis Analysis by Type of Angiogenesis Modulators Exhibit 66: Angiogenesis Therapeutic Products (2005-2012) – French Market Analysis (Current & Future) by Angiogenesis Modulators for Inhibitors and Stimulators in US$ Million (Graphical Representation Included) Exhibit 67: Angiogenesis Therapeutic Products (2006, 2009 and 2012) – Percentage Breakdown of French Market Value by Angiogenesis Modulators for Inhibitors and Stimulators (Graphical Representation Included) B4. Switzerland Swiss Market Analysis Analysis by Type of Angiogenesis Modulators Exhibit 68: Angiogenesis Therapeutic Products (2005-2012) – Swiss Market Analysis (Current & Future) by Angiogenesis Modulators for Inhibitors and Stimulators in US$ Million (Graphical Representation Included) Exhibit 69: Angiogenesis Therapeutic Products (2006, 2009 and 2012) – Percentage Breakdown of Swiss Market Value by Angiogenesis Modulators for Inhibitors and Stimulators (Graphical Representation Included) B5. Rest of Europe Rest of Europe Market Analysis Analysis by Type of Angiogenesis Modulators Exhibit 70: Angiogenesis Therapeutic Products (2005-2012) – Rest of Europe Market Analysis (Current & Future) by Angiogenesis Modulators for Inhibitors and Stimulators in US$ Million (Graphical Representation Included) Exhibit 71: Angiogenesis Therapeutic Products (2006, 2009 and 2012) – Percentage Breakdown of Rest of Europe Market Value by Angiogenesis Modulators for Inhibitors and Stimulators (Graphical Representation Included) C. Asia-Pacific Market Analysis Exhibit 72: Angiogenesis Therapeutic Products (2005-2012) – Asia-Pacific Market Analysis (Current & Future) in US$ Million (Graphical Representation Included) Analysis by Geographic Region Exhibit 73: Angiogenesis Therapeutic Products (2005-2012) – Asia-Pacific Market Analysis (Current & Future) by Geographic Region for Japan and Rest of Asia-Pacific in US$ Million (Graphical Representation Included) Exhibit 74: Angiogenesis Therapeutic Products (2006, 2009 and 2012) – Percentage Breakdown of Asia-Pacific Market Value by Geographic Region for Japan and Rest of Asia-Pacific (Graphical Representation Included) Analysis by Angiogenesis Modulators Exhibit 75: Angiogenesis Therapeutic Products (2005-2012) – Asia-Pacific Market Analysis (Current & Future) by Angiogenesis Modulators for Inhibitors and Stimulators in US$ Million (Graphical Representation Included) Exhibit 76: Angiogenesis Therapeutic Products (2006, 2009 and 2012) – Percentage Breakdown of Asia-Pacific Market Value by Angiogenesis Modulators for Inhibitors and Stimulators (Graphical Representation Included) Analysis by Disease Area Exhibit 77: Angiogenesis Therapeutic Products (2005-2012) – Asia-Pacific Market Analysis (Current & Future) by Disease Area for Cancer, Cardiovascular and Other in US$ Million (Graphical Representation Included) Exhibit 78: Angiogenesis Therapeutic Products (2006, 2009 and 2012) – Percentage Breakdown of Asia-Pacific Market Value by Disease Area for Cancer, Cardiovascular and Other Exhibit 79: List of Major Companies in Asia-Pacific Asia-Pacific Angiogenesis Modulators Market by Country C1. Japan Japanese Market Analysis Analysis by Angiogenesis Modulators Exhibit 80: Angiogenesis Therapeutic Products (2005-2012) – Japanese Market Analysis (Current & Future) by Angiogenesis Modulators for Inhibitors and Stimulators in US$ Million (Graphical Representation Included) Exhibit 81: Angiogenesis Therapeutic Products (2006, 2009 and 2012) – Percentage Breakdown of Japanese Market Value by Angiogenesis Modulators for Inhibitors and Stimulators (Graphical Representation Included) C2. Rest of Asia-Pacific Rest of Asia-Pacific Market Analysis Analysis by Type of Angiogenesis Modulators Exhibit 82: Angiogenesis Therapeutic Products (2005-2012) – Rest of Asia-Pacific Market Analysis (Current & Future) by Angiogenesis Modulators for Inhibitors and Stimulators in US$ Million (Graphical Representation Included) Exhibit 83: Angiogenesis Therapeutic Products (2006, 2009 and 2012) – Percentage Breakdown of Rest of Asia-Pacific Market Value by Angiogenesis Modulators for Inhibitors and Stimulators (Graphical Representation Included) D. Rest of World Market Analysis Exhibit 84: Angiogenesis Therapeutic Products (2005-2012) – Rest of World Market Analysis (Current & Future) in US$ Million (Graphical Representation Included) Analysis by Geographic Region Exhibit 85: Angiogenesis Therapeutic Products (2005-2012) – Rest of World Market Analysis (Current & Future) by Geographic Region for Latin America and Other in US$ Million (Graphical Representation Included) Exhibit 86: Angiogenesis Therapeutic Products (2006, 2009 and 2012) – Percentage Breakdown of Rest of World Market Value by Geographic Region for Latin America and Other (Graphical Representation Included) Analysis by Angiogenesis Modulators Exhibit 87: Angiogenesis Therapeutic Products (2005-2012) – Rest of World Market Analysis (Current & Future) by Angiogenesis Modulators for Inhibitors and Stimulators in US$ Million (Graphical Representation Included) Exhibit 88: Angiogenesis Therapeutic Products (2006, 2009 and 2012) – Percentage Breakdown of Rest of World Market Value by Angiogenesis Modulators for Inhibitors and Stimulators (Graphical Representation Included) Analysis by Disease Area Exhibit 89: Angiogenesis Therapeutic Products (2005-2012) – Rest of World Market Analysis (Current & Future) by Disease Area for Cancer, Cardiovascular and Other in US$ Million (Graphical Representation Included) Exhibit 90: Angiogenesis Therapeutic Products (2006, 2009 and 2012) – Percentage Breakdown of Rest of World Market Value by Disease Area for Cancer, Cardiovascular and Other Rest of World Angiogenesis Market by Region D1. Latin America Latin American Market Analysis Analysis by Angiogenesis Modulators Exhibit 91: Angiogenesis Therapeutic Products (2005-2012) – Latin America Market Analysis (Current & Future) by Angiogenesis Modulators for Inhibitors and Stimulators in US$ Million (Graphical Representation Included) Exhibit 92: Angiogenesis Therapeutic Products (2006, 2009 and 2012) – Percentage Breakdown of Latin America Market Value by Angiogenesis Modulators for Inhibitors and Stimulators (Graphical Representation Included) D2. Rest of World (Excluding Latin America) Other Region in Rest of World’s Market Analysis Analysis by Angiogenesis Modulators Exhibit 93: Angiogenesis Therapeutic Products (2005-2012) – Other Region of Rest of World Market Analysis (Current & Future) by Angiogenesis Modulators for Inhibitors and Stimulators in US$ Million (Graphical Representation Included) Exhibit 94: Angiogenesis Therapeutic Products (2006, 2009 and 2012) – Percentage Breakdown of Other Region of Rest of World Market Value by Angiogenesis Modulators for Inhibitors and Stimulators (Graphical Representation Included) Exhibit 95: List of Major Companies in Rest of World (Excluding Latin America) 5. Angiogenesis Modulators - The Industry Outlook V. CORPORATE DIRECTORY

Companies Mentioned

Abbott Laboratories (USA) Adnexus Therapeutics, Inc. (USA) Aeterna Zentaris, Inc. (Canada) Alcon, Inc. (USA) Amgen, Inc. (USA) Angiotech Pharmaceuticals, Inc. (Canada) Ångstrom Pharmaceuticals, Inc. (USA) Antisoma plc (UK) Astrazeneca plc (UK) Bayer Healthcare AG (Germany) Callisto Pharmaceuticals, Inc. (USA) Cardium Therapeutics, Inc. (USA) Celgene Corporation (USA) Chugai Pharmaceutical Co., Ltd. (Japan) Collagenex Pharmaceuticals, Inc. (USA) Eisai, Inc. (USA) Entremed, Inc. (USA) F.Hoffmann-La Roche Ltd. (Switzerland) Genaera Corporation (USA) Genentech, Inc. (USA) Genvec, Inc. (USA) Genzyme Corporation (USA) Human Genome Sciences, Inc. (USA) Imclone Systems, Inc. (USA) Intradigm Corporation (USA) Merck & Co., Inc. (USA) Merck KGaA (Germany) Novartis AG (Switzerland) OSI Pharmaceuticals, Inc. (USA) Oxigene, Inc. (USA) Pfizer, Inc. (USA) Progen Industries Ltd. (Australia) TAP Pharmaceutical Products, Inc. (USA) UCB SA (Belgium)